Hematologic Oncology

Explore key insights on operationalizing bispecific antibodies in community oncology, outpatient step-up dosing, and shared staffing infrastructure.

Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.

Investigators evaluated how tisagenlecleucel and cilta-cel altered adverse effect timelines for patients treated for hematologic malignancies.

Ralph V. Boccia, MD, FACP, discussed the operational hurdles of administering bispecific antibodies in community settings.

Novel bispecifics may bridge gaps in care, especially among patients in rural settings, according to Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA.

Researchers have reported that CD7 may be a viable CAR T-cell target in a subset of relapsed/refractory acute myeloid leukemia, and that fratricide-resistant CD7 CAR T cells can induce deep remissions with an encouraging early safety profile.

Researchers have demonstrated that BET inhibition can reverse key immunologic and fibrotic features of bronchiolitis obliterans syndrome, a severe pulmonary form of chronic GVHD.

The RUBY trial demonstrates that disrupting the BCL11A binding site in the γ-globin promoters can normalize hemoglobin in severe sickle cell disease.

The FDA has extended the PDUFA action date to July 6, 2026, for approving Orca-T across different hematologic malignancies.

The real-world CHRONOS study may set a new benchmark for the third-line management of acute graft-vs-host-disease with gastrointestinal involvement.

A landmark Nature study demonstrates targeted CRISPR-based CAR transgene integration in living patients' T cells without ex vivo manufacturing.

An intern doctor at Al-Sabah Children’s Hospital sheds light on health care delivery gaps in a resource-limited setting.

Maintaining quality of life should be a key focus in the treatment of different hematologic malignancy populations, explained Guenther Koehne, MD.

The FDA has set a Prescription Drug User Fee Act date for the third quarter of 2026 for approving rusfertide for polycythemia vera.

Yan Leyfman, MD, shared key clinical and practice-shaping insights related to cellular therapy from the 2026 Tandem Meetings.

Although AI can be effective in hematologic malignancies and palliative care, it must be used ethically, said Ram Prakash Thirugnanasambandam, MBBS.

AI-based models must be trained on data derived from diverse patient populations to eliminate potential bias in the context of palliative care.

Findings presented at the 2026 Tandem Meetings showed that an accelerated immune constitution of donor-derived CD4-positive T cells was observed with TRX103.

Safety-optimized CAR-T platforms and supportive-care breakthroughs highlight a maturing field focused on access, durability, and real-world implementation.

Data from the phase 1/2 CADENZA trial support pivekimab sunirine as a potential standard treatment for this rare blood cancer population.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

Researchers have generated a high-resolution spatial atlas of the human gastrointestinal tract in aGVHD, revealing epithelial disruption and unexpected immune cell patterns that reshape how the disease is understood.

Investigators are currently evaluating zavabresib plus ruxolitinib among patients with myelofibrosis in the phase 1 PROMise study.

The FDA has assigned a PDUFA date of August 30, 2026, for approving ropeginterferon alfa-2b-njft among adults with essential thrombocytopenia.

Patients with BPDCN who did not achieve a complete or clinical complete response during treatment experienced a restoration of hematopoiesis.